Roche ’s Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma
Roche will today present results from a Phase Ib study evaluating the efficacy and safety of Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as a treatment for people with unresectable hepatocellular carcinoma (HCC), the most common form of liver cancer, who have not received prior systemic therapy. (Source: Roche Media News)
Source: Roche Media News - September 27, 2019 Category: Pharmaceuticals Source Type: news
Roche ’s Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma
Roche will today present results from a Phase Ib study evaluating the efficacy and safety of Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as a treatment for people with unresectable hepatocellular carcinoma (HCC), the most common form of liver cancer, who have not received prior systemic therapy. (Source: Roche Investor Update)
Source: Roche Investor Update - September 27, 2019 Category: Pharmaceuticals Source Type: news
Medicines regulator accepts ‘off label’ use of Avastin for wet AMD
Move will enable thousands of patients to be treated at fraction of the cost, say commissioners Related items fromOnMedica New cancer drug ‘refused’ by NICE Experts call on regulators to revisit nalmefene decision 75% of reappraised CDF drugs approved for NHS Controversial new drug approval system unveiled MPs slam government for its poor management of Cancer Drugs Fund (Source: OnMedica Latest News)
Source: OnMedica Latest News - September 20, 2019 Category: UK Health Source Type: news
UCLA oncologist Dennis Slamon wins 2019 Lasker Award for clinical medical research
Physician-scientist Dr. Dennis Slamon, professor and chief of hematology/oncology at the David Geffen School of Medicine at UCLA, has been awarded the 2019 Lasker-DeBakey Clinical Medical Research Award for the groundbreaking development of breast cancer drug Herceptin (trastuzumab), a lifesaving therapy for women with HER2-positive breast cancer. He shares the award with H. Michael Shepard, an American cancer researcher honored for work he completed at biotechnology company Genentech; and Axel Ullrich, a German cancer researcher from the Max Planck Institute of Biochemistry.The Albert and Mary Lasker Foundation honored Sl...
Source: UCLA Newsroom: Health Sciences - September 10, 2019 Category: Universities & Medical Training Source Type: news
Genentech nears trade secrets suit settlement with Taiwanese company but still targeting former employees
Biotech powerhouse Genentech Inc. is close to settling a with a Taiwanese company that allegedly stole trade secrets and planned to launch a look-alike version of one of Genentech's most popular drugs.
The settlement between the South San Francisco-based U.S. unit of drug giant Roche and JHL Biotech Inc. requires the Taiwanese company to stop development of biosimilar versions of Genentech's cancer drugs Rituxan, Herceptin and Avastin — all multibillion-dollar biologics — and the cystic fibr osis… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 7, 2019 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
Genentech nears trade secrets suit settlement with Taiwanese company but still targeting former employees
Biotech powerhouse Genentech Inc. is close to settling a with a Taiwanese company that allegedly stole trade secrets and planned to launch a look-alike version of one of Genentech's most popular drugs.
The settlement between the South San Francisco-based U.S. unit of drug giant Roche and JHL Biotech Inc. requires the Taiwanese company to stop development of biosimilar versions of Genentech's cancer drugs Rituxan, Herceptin and Avastin — all multibillion-dollar biologics — and the cystic fibr osis… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 7, 2019 Category: Biotechnology Authors: Ron Leuty Source Type: news
Pacifico National, Inc. dba AmEx Pharmacy Issues Voluntary Nationwide Recall for all Lots of Bevacizumab
AmEx Pharmacy today announces a voluntary recall of all Lots of Bevacizumab 1.25mg/0.05mL 31G Injectable and all Lots of Bevacizumab 2.5mg/0.1ml Normject TB Injectable that are within expiry to the healthcare provider level. These lots are being recalled out of an abundance of caution following an F (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 31, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Pacifico National, Inc. dba AmEx Pharmacy Issues Voluntary Nationwide...
AmEx Pharmacy today announces a voluntary recall of all Lots of Bevacizumab 1.25mg/0.05mL 31G Injectable and all Lots of Bevacizumab 2.5mg/0.1ml Normject TB Injectable that are within expiry to the...(PRWeb August 30, 2019)Read the full story at https://www.prweb.com/releases/pacifico_national_inc_dba_amex_pharmacy_issues_voluntary_nationwide_recall_for_all_lots_of_bevacizumab/prweb16539042.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 30, 2019 Category: Pharmaceuticals Source Type: news
Dr Reddy's launches Roche's Avastin biosimilar in India
The launch of Versavo is another step in that journey and helps in strengthening the company's oncology portfolio. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 18, 2019 Category: Pharmaceuticals Source Type: news
Lynparza Phase III PAOLA-1 trial met primary endpoint as 1st-line maintenance treatment with bevacizumab for advanced ovarian cancer
AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced positive results from the Phase III PAOLA-1 trial in women with advanced ovarian cancer. The trial, in the 1st-line maintenance setting, compared Lynparza (olaparib) added to standard-of-care (SoC) bevacizumab vs. bevacizumab alone in women with or without BRCA gene mutations. (Source: World Pharma News)
Source: World Pharma News - August 14, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
What Is the Optimal Maintenance Therapy in Advanced NSCLC?
A phase III trial found bevacizumab and pemetrexed were effective as a maintenance therapy, but researchers do not recommend it to treat non–small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - August 5, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
Bevacizumab Benefit in Large-Volume Ovarian Cancer Bevacizumab Benefit in Large-Volume Ovarian Cancer
Although there was no benefit in overall survival in the primary treatment of ovarian cancer with maintenance bevacizumab, some hope remains for patients with large-volume disease.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 1, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Amgen and Allergan's MVASI ™ (bevacizumab-awwb) and KANJINTI™ (trastuzumab-anns) now available in the United States
Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) announced that MVASI™ (bevacizumab-awwb), a biosimilar to Avastin® (bevacizumab), and KANJINTITM (trastuzumab-anns), a biosimilar to Herceptin® (trastuzumab), are now available in the United States (U.S.). (Source: World Pharma News)
Source: World Pharma News - July 23, 2019 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news
Amgen, Allergan launch first anti-cancer biosims in U.S.
Amgen and Allergan have announced the launch of Mvasi, a bevacizumab biosimilar referencing Avastin, and Kanjinti, a trastuzumab biosimilar referencing Herceptin, in the United States. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - July 19, 2019 Category: Pharmaceuticals Source Type: news
Avastin Improves Quality of Life for Mesothelioma Patients
A research team from France has documented the health-related quality-of-life benefits of adding Avastin (bevacizumab) to chemotherapy for pleural mesothelioma patients, endorsing its addition to standard-of-care treatment.
The recent quality-of-life analysis was a secondary endpoint of an earlier, multicenter clinical trial in France that showed an almost three-month median survival improvement when adding Avastin.
The latest study demonstrated that adding Avastin to cisplatin and Alimta (pemetrexed) did not negatively impact quality of life — a problem with several other cancers because of the increased toxicity.
“Co...
Source: Asbestos and Mesothelioma News - July 8, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news
